Appointment of Dr. Dana T. Aftab: Exelixis, Inc. has appointed Dr. Dana T. Aftab as Executive Vice President of Research and Development, where he will manage drug discovery, translational research, product development, and medical affairs.
Dr. Aftab's Experience: With over 25 years at Exelixis, Dr. Aftab has been pivotal in the development of cabozantinib, transforming it from an orphan drug into a global oncology franchise.
Company Overview
Exelixis' Focus: The company is dedicated to innovating next-generation oncology medicines, with a robust pipeline that includes cabozantinib and zanzalintinib, the latter undergoing multiple pivotal trials.
Leadership Transition: Amy Peterson, M.D., who previously held the position of Executive Vice President, Product Development & Medical Affairs, has left the company.
Future Outlook
Strategic Goals: Exelixis aims to expand its product portfolio to address a wider range of tumor types and indications, leveraging its investment in scientific research and partnerships.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future plans and potential risks, emphasizing that actual results may differ from expectations.
EXEL
$42.595+Infinity%1D
Analyst Views on EXEL
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.33 USD with a low forecast of 30.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.33 USD with a low forecast of 30.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
8 Hold
0 Sell
Moderate Buy
Current: 42.000
Low
30.00
Averages
45.33
High
56.00
Current: 42.000
Low
30.00
Averages
45.33
High
56.00
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis with a Peer Perform rating and no price target. Zanzalintinib is unlikely to fully replenish cabozantinib's potential lost revenues, the analyst tells investors.
Morgan Stanley
Overweight
maintain
$44 -> $45
2025-11-07
Reason
Morgan Stanley
Price Target
$44 -> $45
2025-11-07
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Exelixis to $45 from $44 and keeps an Overweight rating on the shares. Cabo continues to demonstrate sustained demand and the NET launch progresses well with roughly $100M expected in contribution to 2025 net product revenue, the analyst tells investors in a research note. The firm added the company expects to submit the NDA in previously treated mCRC in December 2025, pending the U.S. government re-opening.
UBS
Neutral
maintain
$35 -> $40
2025-11-06
Reason
UBS
Price Target
$35 -> $40
2025-11-06
maintain
Neutral
Reason
UBS raised the firm's price target on Exelixis to $40 from $35 and keeps a Neutral rating on the shares.
Stifel
Stephen Willey
Hold
maintain
$41 -> $43
2025-11-05
Reason
Stifel
Stephen Willey
Price Target
$41 -> $43
2025-11-05
maintain
Hold
Reason
Stifel analyst Stephen Willey raised the firm's price target on Exelixis to $43 from $41 and keeps a Hold rating on the shares following a Q3 earnings announcement and corporate update that the firm says had "no significant surprises.
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
